Business Context and Reporting Period
This Form 8-K is filed by BioSig Technologies, Inc. (not Streamex Corp.) on December 22, 2016, reporting events occurring on December 16, 2016, and December 22, 2016. The filing details the consummation of the third and fourth closings under a Unit Purchase Agreement dated October 28, 2016.
Key Financial Metrics
- Proceeds from Recent Closings: Approximately $1,715,000 raised from the third and fourth closings (December 16 and 22, 2016).
- Units Issued (Recent): 1,143,334 units issued to accredited investors.
- Unit Composition: Each unit consists of one share of common stock and a warrant to purchase 0.5 shares of common stock.
- Exercise Price: Warrants are exercisable at $1.50 per share.
- Total Program Proceeds: Including the first closing (October 28) and second closing (November 23), the aggregate gross proceeds from all four closings total approximately $2,384,851.
- Capital Structure Impact: The December 16 issuance increased the number of common shares outstanding by more than 5% since the November 3, 2016 report.
Note: The filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the significant dilution of existing shareholders due to the issuance of 1,143,334 new units in December, representing a >5% increase in outstanding common stock since the prior 8-K filing. Additionally, the company has secured additional liquidity through the completion of the fourth closing under the purchase agreement.
Outlook, Risks, and Contingencies
- Regulatory Status: Securities were sold unregistered under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933.
- Investor Qualifications: All investors represented they were "accredited investors."
- Registration Rights: Investors in the second, third, and fourth closings entered into a Registration Rights Agreement dated October 28, 2016.
- Management Commentary: The filing contains no forward-looking guidance, risk factors, or management commentary beyond the factual description of the transaction.
Investor Verification Checklist
- Verify the total number of outstanding shares post-December 22 issuance to assess the exact dilution impact.
- Review the Registration Rights Agreement to understand potential future registration obligations and market impact.
- Confirm the use of proceeds from the $2.38 million raised to determine if it addresses immediate liquidity needs or funds specific operations.
- Check for any subsequent filings regarding the exercise of the warrants issued in this transaction.